While AI can accelerate the ideation phase of drug discovery, the primary bottleneck remains the slow, expensive, and human-dependent clinical trial process. We are already "drowning in good ideas," so generating more with AI doesn't solve the fundamental constraint of testing them.

Related Insights

Wet lab experiments are slow and expensive, forcing scientists to pursue safer, incremental hypotheses. AI models can computationally test riskier, 'home run' ideas before committing lab resources. This de-risking makes scientists less hesitant to explore breakthrough concepts that could accelerate the field.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

True creative mastery emerges from an unpredictable human process. AI can generate options quickly but bypasses this journey, losing the potential for inexplicable, last-minute genius that defines truly great work. It optimizes for speed at the cost of brilliance.

The era of guaranteed progress by simply scaling up compute and data for pre-training is ending. With massive compute now available, the bottleneck is no longer resources but fundamental ideas. The AI field is re-entering a period where novel research, not just scaling existing recipes, will drive the next breakthroughs.

AI can produce scientific claims and codebases thousands of times faster than humans. However, the meticulous work of validating these outputs remains a human task. This growing gap between generation and verification could create a backlog of unproven ideas, slowing true scientific advancement.

AI can generate hundreds of statistically novel ideas in seconds, but they lack context and feasibility. The bottleneck isn't a lack of ideas, but a lack of *good* ideas. Humans excel at filtering this volume through the lens of experience and strategic value, steering raw output toward a genuinely useful solution.

The true exponential acceleration towards AGI is currently limited by a human bottleneck: our speed at prompting AI and, more importantly, our capacity to manually validate its work. The hockey stick growth will only begin when AI can reliably validate its own output, closing the productivity loop.

Advanced AI tools like "deep research" models can produce vast amounts of information, like 30-page reports, in minutes. This creates a new productivity paradox: the AI's output capacity far exceeds a human's finite ability to verify sources, apply critical thought, and transform the raw output into authentic, usable insights.

The mantra 'ideas are cheap' fails in the current AI paradigm. With 'scaling' as the dominant execution strategy, the industry has more companies than novel ideas. This makes truly new concepts, not just execution, the scarcest resource and the primary bottleneck for breakthrough progress.